CHEK1 and posterior cortical atrophy: Given the subsets of PCa harboring homologous recombination repair defects, TNPs could be employed for the purposes of synthetic lethality by co‐encapsulating PARP inhibitors with DNA damage‐inducing agents or Ataxia telangiectasia and Rad3‐related (ATR)/checkpoint kinase 1 (CHK1) inhibitors.